Introduction
Invasive aspergillosis (IA) may develop as a complication in up to 30% of patients undergoing allogeneic hematopoietic SCT (HSCT). [1] [2] [3] Data from prospective and retrospective studies indicate that response rates for IA are low among allogeneic HSCT recipients, and mortality is higher compared with autologous HSCT patients. [4] [5] [6] Therapeutic decisions for these patients are difficult and it is not always possible to maintain an acceptable balance between toxicity and efficacy with commonly used antifungal regimens for IA. [7] [8] [9] Caspofungin is an exception in that, it has proven not only to be effective against IA, but has been well tolerated even among patients who were intolerant to or failed previous therapy. [9] [10] [11] The objective of this study was to evaluate caspofungin as first-line therapy in the treatment of proven and probable IA in patients who had received allogeneic HSCT. Proven or probable IA was defined by European Organisation for Research and Treatment of Cancer-Mycosis Study Group (EORTC-MSG) criteria, and based on microscopy, culture, histopathology or Aspergillus galactomannan detection assay. 12 Unlike most studies in IA, patients with a halo sign only (without proper microbiological documentation) were excluded. A second stratum of this study evaluating caspofungin first-line monotherapy in patients with hematological malignancies and autologous HSCT was designed separately and the results have been reported separately. 13 
Patients and methods

Study design
This phase II, open-label, non-randomized, multicenter study was designed to evaluate the efficacy and safety of caspofungin as first-line monotherapy in patients with IA and allogeneic HSCT. The protocol was approved by the EORTC protocol review committee and the institutional review boards of all participating centers, and the trial was conducted in accordance with Good Clinical Practices and the Declaration of Helsinki. Written informed consent was obtained from each patient and enrollment was centrally coordinated at the EORTC Data Center using a secure web-based system. A Data Review Committee assessed eligibility and response for each case.
Patient population EORTC-MSG definitions were used to determine whether patients had proven, probable, or possible IA. 12 Only patients with proven or probable IA strictly according to EORTC-MSG criteria that require positive microscopy, culture, histopathology or galactomannan Ag in serum or in bronchoalveolar lavage (BAL) fluid were eligible for this study. Patients with possible IA, namely those with halo sign only but without mycological documentation, could be enrolled but had to be upgraded to proven or probable IA within 7 days of registration based on tests performed before or within 48 h after registration. Patients not upgraded were discontinued from the study but assessed for safety and treated for IA at the discretion of the investigator. All patients were at least 18 years of age and had not received previous therapy with an echinocandin, more than 72 h of previous empirical antifungal therapy, or any investigational agent within 14 days before registration. Antifungal prophylaxis was discontinued at study entry. Patients were excluded on the basis of known allergy or adverse reaction to echinocandins, severe renal failure, significant liver function test abnormalities (increases in alanine aminotransferase or aspartate aminotransferase 45 Â upper limit of normal; serum bilirubin/alkaline phosphatase 45 Â upper limit of normal; Child Pugh score X9), hepatic insufficiency, known bacterial infection not adequately treated, documented human immunodeficiency virus infection, pregnant/lactating women, conditions hampering compliance or a Karnofsky score p20.
Treatment
Patients received a 70 mg loading dose of caspofungin on day 1, followed by 50 mg/day for at least 15 days and up to 12 weeks (maximum treatment duration). Dose modifications were made for patients with body weight 480 kg (70 mg/day) or moderate hepatic insufficiency (after 70 mg loading dose, 35 mg/day). Addition or modification to protocol therapy in the absence of an evaluation of efficacy was considered a treatment failure. Patients with stable disease were requested to continue study treatment for at least 28 days to obtain a final efficacy evaluation.
Efficacy and safety end points and evaluations
The primary end point was the proportion of patients with complete response or partial response to caspofungin at the end of caspofungin therapy. Secondary end points included the response rate at week 12 after the start of caspofungin treatment, survival rate at week 12 and safety. The primary response and survival analyses were performed in the modified intent-to-treat patient population, which included all patients with mycologically confirmed probable/proven IA who received at least one dose of caspofungin treatment. The per protocol group included eligible patients who received a minimum of 15 days of caspofungin treatment but excluded those whose treatment was modified without adequate reason, according to the Data Review Committee. Safety was assessed in all patients who started treatment, including those who were ineligible or not upgraded.
Patient evaluations included medical history, physical examination, Karnofsky score, laboratory assessments (hematology and chemistry profiles) at study entry, weekly while on treatment, and up to 30 days after end of study treatment. Repeated Aspergillus galactomannan tests and computed tomography scans or magnetic resonance imaging of chest or any other site of infection were carried out in patients if clinically indicated. Sputum cultures, BAL, biopsy of pulmonary and extrapulmonary lesions, and CSF examination were carried out if clinically appropriate. A galactomannan index X0.7 was considered to be positive. 14, 15 Definite infection required a positive histopathology or culture from a sterile site (for example, lung biopsy). Two consecutive positive galactomannan tests in blood or one positive test in BAL or a positive sputum or BAL microscopy or culture were needed for a diagnosis of probable infection.
Study evaluations were carried out using standard response assessment criteria. 16 Complete response required resolution of all attributable clinical signs and symptoms, disappearance of all radiological lesions, and no new clinical symptoms or signs or radiological abnormalities compatible with IA (in the case of a residual scar, a decrease of at least 90% in the sum of the area of the attributable measurable lesions was required). Partial response required major improvement of fever and attributable clinical signs and symptoms, with no new clinical symptoms or signs or radiological abnormalities and at least a 50% decrease in the sum of the areas of the attributable measurable lesions. Stable disease was defined as the absence of complete or partial response or progression. Disease progression was defined as worsening of baseline clinical signs and symptoms attributable to IA, or appearance of new clinical signs or symptoms or new radiological lesions compatible with IA regardless of localization, or an increase in the sum of areas of the attributable measurable clinical and radiological lesions, or death likely because of aspergillosis and death because of any cause at any time if response could not be assessed before death.
Statistical considerations
On the basis of a one-stage Fleming design with significance level of 0.10 and 95% power to detect an effective therapy if the true response rate was at least 33% (null hypothesis: true response rate p13%), this therapy would be recommended for further investigation in a phase III trial if at least 8 out of 37 eligible patients had a response. It was estimated that a total of 62 patients had to be registered to have 37 eligible patients. Fisher's exact test was used to test the statistical significance of differences in response rates in discrete data. Baseline and end of therapy hepatic and renal function tests were compared using the Wilcoxon matched pairs test. The 95% confidence intervals for proportions were calculated using exact binomial distribution probabilities.
Results
In all, 42 patients were enrolled at 13 centers between May 2005 and February 2008. At enrollment, 11 patients had proven/probable IA and 31 had possible IA. A total of 13 (42%) of the 31 patients with possible IA were upgraded to proven/probable IA. The study was terminated early because of slow accrual. Twenty-four patients were eligible for the modified intent-to-treat population and all of these patients were also included the per protocol population. With 24 evaluable patients, the study had a power of 85% to reject the null hypothesis in the case of a true response rate of at least 33% at the chosen significance level of 10%.
Patient baseline characteristics and demographics
All patients enrolled in this study had allogeneic HSCT and mycological documentation of proven or probable IA (Table 1 ). All infections were localized to the lower respiratory tract. Acute or chronic GVHD was present in 15 patients (63%). Acute leukemia and lymphoma were the most common reasons for the transplantation. Twelve patients (50%) were neutropenic (o500 cells/ml) at the start of caspofungin therapy; 54% had been neutropenic for more than 10 days during the 60 days before enrollment. The median Karnofsky score at enrollment was 70 (range: 30-90). Transplants were from unrelated donors in 16 patients (67%). In total, 10 patients (42%) received steroids, 14 (58%) received a calcineurin inhibitors, 2 (7%) received sirolimus and 7 (29%) received other immunosuppressive agents at baseline or during caspofungin therapy. Previous mold-active antifungal therapy was given to 10 patients as prophylaxis or empiric therapy ( Table 1) .
The causative pathogen was isolated in 9/24 patients (Aspergillus fumigatus, n ¼ 4; Aspergillus flavus, n ¼ 1; A. fumigatus and A. flavus, n ¼ 1; Aspergillus nidulans, n ¼ 1; Aspergillus spp. n ¼ 2). Positive Aspergillus galactomannan Ag in BAL (n ¼ 7) or serum (n ¼ 15) was found in 22 out of 24 patients.
Response to treatment
The median duration of caspofungin treatment was 24 days (range: 2-85 days). At the end of caspofungin therapy, 10 out of 24 patients (42%; 95% confidence interval 22-63%) achieved treatment success (complete or partial response) ( Table 2) . At week 12, 8 out of 24 patients (33%; 95% confidence interval 16-55%) achieved treatment success. Success rates at the end of caspofungin therapy by baseline characteristics are shown in Table 3 . Baseline neutropenic status did not appear to affect the success rate.
The survival rate at week 6 was 79% (19 out of 24). At week 12, 50% of patients (n ¼ 12)) were alive (Figure 1) . Twelve patients died because of IA (n ¼ 5), hemorrhage with aspergillosis (n ¼ 1), underlying disease with aspergillosis (n ¼ 3), and concomitant (n ¼ 1) or subsequent infection without aspergillosis (n ¼ 2). Nine out of 18 patients (50%) with controlled cancer were alive at week 12 compared with two out of five patients (40%) with Table 1 Baseline characteristics in the modified intent-to-treat patient population (n ¼ 24) Neutropenia (o500/ml) at the start of study treatment 12 (50) Neutropenia (o500/ml) for 410 days in previous 60 days 13 (54)
Mycology
Galactomannan in blood X0. uncontrolled cancer (P ¼ ns). A similar proportion of patients with (50%) and without neutropenia at entry (50%) were alive at week 12.
Safety
No serious caspofungin-related adverse events or adverse events leading to discontinuation were observed in this study. Drug-related adverse events were reported for 3 of the 42 patients included in the safety analysis (7%). These laboratory adverse events, categorized as likely related to caspofungin by the investigators, included increased bilirubin and increased g-glutamyltransferase (n ¼ 1, grade 4 and grade 2, respectively), increased alanine aminotransferase and aspartate aminotransferase (n ¼ 1, grade 3) and hypokalemia (n ¼ 1, grade 3). Creatinine, alanine aminotransferase, aspartate aminotransferase, g-glutamyltransferase and alkaline phosphatases serum levels did not differ at end of caspofungin therapy as compared with baseline in the 42 patients of the safety population (median duration of caspofungin therapy: 13 days, range: 2-85 days) (Figure 2 ). Results did not differ when analysis was restricted to the 24 patients in the modified intent-to-treat population (median duration of caspofungin therapy: 24 days, range: 2-85 days).
Discussion
Caspofungin was found to be a well-tolerated, effective first-line therapy in patients with IA and allogeneic HSCT. At the end of caspofungin therapy, 42% (95% confidence interval 22-63%) of patients had a favorable outcome. The survival rate was 79% at week 6 and 50% at week 12.
The response rates achieved at the end of caspofungin therapy were notable considering the 24 day median duration of therapy and the severity of the underlying immunosuppression. Our study included only patients with the highest risk of IA who had the worst prognosis: allogeneic HSCT recipients. 17 In contrast, allogeneic HSCT patients represented a minority of the cases in the two major clinical trials conducted in IA during the last decade. 16, 18 A favorable response rate of 32.4% was reported in 37 patients treated with voriconazole and 13.3% in 30 patients treated with amphotericin B deoxycholate. 16 In a study comparing two doses of liposomal amphotericin B (AmBiLoad trial), the best tolerated dose (3 mg/kg daily) provided a 47% favorable response rate in 17 patients with allogeneic HSCT. 18 In both of these studies, allogeneic HSCT was associated with a worse outcome than other hematologic conditions. Similar observations have been reported from a large, retrospective single-center study. 4 Our study was characterized by very stringent inclusion and assessment criteria. Strict adherence to EORTC/MSG criteria for the case definition is the exception rather than the rule in designing trials evaluating regimens for IA. Following these criteria strictly made our trial unique. Only patients with documented mycological criteria were considered to have probable or proven IA and enrolled in our study. In contrast, a high proportion of high-risk patients with halo sign only were enrolled in the AmBiLoad trial and to a lesser extent in the voriconazole trial; 16, 18 thus, many patients did not have mycological confirmation of IA in these two studies. It has been shown that patients with non-mycologically confirmed IA (possible cases according to EORTC/MSG criteria) have much better outcomes than patients with strictly defined disease. 4 As such, our results are not suitable for comparison with these other trials that included patients with less rigorously defined disease. 16, 18 In addition, the response criteria used in the AmBiLoad study allowed the disappearance of a halo sign or a decrease in lesion size without indication of the percentage reduction as a criteria for partial response. 19 Our assessments were based on stringent, predefined criteria similar to Table 2 Response rates at the end of therapy in the modified intent-to-treat patient population (n ¼ 24)
Response
End of caspofungin therapy n (%) those used for the voriconazole trial; a partial response required a decrease of at least 50% of the sum of the area of the baseline radiological lesions in conjunction with significant symptomatic improvement.
Recent data suggest that survival should be assessed at week 6 rather than week 12 as most deaths occurring after week 6 are related to the underlying condition. 20, 21 Interestingly, survival analysis showed 79% survival at week 6 in our patients confirming the efficacy of caspofungin against IA in allogeneic HSCT patients. Even at 12 weeks, half the patients survived.
As in previous studies caspofungin had a favorable safety profile. 22, 23 This point is critical in allogeneic HSCT recipients who usually require multiple concomitant medications including immunosuppressive agents. The absence of nephrotoxicity with caspofungin is in contrast to the high rate of nephrotoxicity observed with amphotericin B and its lipid formulations. 16, 18, 24 Importantly, drugdrug interactions leading to potentially severe adverse events have been reported between triazole antifungal agents and various other drugs, especially the calcineurin inhibitors and sirolimus. These interactions are explained by inhibition of various cytochrome P450 isoenzymes by the triazole antifungals.
9,25 Two-thirds of our patients received cyclosporine, tacrolimus or sirolimus concomitantly with caspofungin without any indication of relevant interactions. No renal toxicity, except one case of hypokalemia, was attributed by investigators to caspofungin, and neither of the two patients who experienced increased transaminases or increased bilirubin received any of these immunosuppressants concomitantly with caspofungin. Moreover, there was no significant worsening in liver function tests in the 42 patients of the safety population during caspofungin therapy. Our results contrast with those of Morrissey et al. 26 who suggested an increased risk for laboratory hepatotoxicity, however, rarely clinically relevant, in a limited number of patients (n ¼ 8) receiving concomitant caspofungin and CYA.
In conclusion, this study confirmed that caspofungin is an effective first-line therapy for the treatment of mycologically documented IA in allogeneic HSCT patients. Caspofungin was found to be well tolerated, with a favorable safety profile in this high risk patient population. 
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